Citadel Advisors
TNXP icon

Citadel Advisors’s Tonix Pharmaceuticals TNXP Stock Holding History

Citadel Advisors’s Portfolio TNXP Stock Details TNXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$577K Buy
45,200
+27,800
+160% +$359K ﹤0.01% 9516
2026
Q1 		$239K Sell
17,400
-22,400
-56% -$345K ﹤0.01% 11014
2025
Q4 		$622K Buy
+39,800
New +$734K ﹤0.01% 8504
2016
Q4 		– Hold
0
– -$9K – 7841
2016
Q3 		– Hold
0
– – – 7147
2016
Q2 		– Hold
0
– – – 6457
2016
Q1 		– Hold
0
– -$28K – 7959
2015
Q4 		– Hold
0
– – – 7711
2015
Q3 		– Hold
0
– – – 8152
2015
Q2 		– Hold
0
– – – 8129
2015
Q1 		– Hold
0
– – – 8323
2014
Q4 		– Hold
0
– – – 8421

Other funds holding TNXP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
II
Ishara Investments Los Angeles, California $136M AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citadel Advisors's TNXP Position: Q2 2026 in Review

Citadel Advisors reduced its Tonix Pharmaceuticals (TNXP) stake by 58% in Q2 2026, selling an estimated $3.52M and leaving 195,859 shares worth $2.5M. The position accounts for ﹤0.01% of the portfolio, ranked #6061.

Citadel Advisors first reported a position in TNXP in Q2 2020 and has held it in 8 quarters since. The position peaked at $6.44M in Q1 2026. 102 funds tracked by Wall St. Rank hold TNXP as of Q2 2026.

  • Citadel Advisors held 195,859 shares of Tonix Pharmaceuticals worth $2.5M as of Q2 2026.
  • Citadel Advisors sold 272,853 Tonix Pharmaceuticals shares in Q2 2026, an estimated $3.52M.
  • Tonix Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #6061 holding.
  • Citadel Advisors first reported a position in Tonix Pharmaceuticals in Q2 2020 and has held it in 8 quarters since.
  • Citadel Advisors's Tonix Pharmaceuticals position peaked at $6.44M in Q1 2026.
  • 102 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.